Francis Willard Sarena
CIK 1423786 · Chief Operating Officer · last filed 2025-10-30
Francis Willard Sarena is a Chief Operating Officer who has filed 49 SEC Form 4 insider transactions across 6 companies since 2008. The most recent filing, for ETNB, was dated Oct 30, 2025. Across all open-market trades the lifetime net is −$3.8M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $172.8K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$172.8K
6
49
-$3.82M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| 89bio, Inc. (ETNB) Delisted | Chief Operating Officer | 0 | $14.84 | $0 | $0 | 4 | 2025-10-30 |
| Apexigen, Inc. (APGNW) Delisted | President and COO | 155,419 | $0.03 | $4.1K | $0 | 4 | 2023-06-23 |
| FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | Chief Strategy Officer | 122,337 | $38.00 | $4.65M | -$1.46M | 14 | 2021-04-19 |
| FIVE PRIME THERAPEUTICS, INC. (XLRN) Delisted | Chief Strategy Officer | 82,248 | $178.75 | $14.70M | -$2.37M | 17 | 2019-09-04 |
| FACT | VP Gen Counsel & Secy | 16,227 | $10.65 | $172.8K | $0 | 6 | 2010-04-21 |
| PDL BIOPHARMA, INC. (PDLI) Delisted | VP/Gen Counsel/Secy | 5,756 | — | — | $0 | 2 | 2008-09-17 |
Recent Filings
49 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-10-30 | 89bio, Inc. (ETNB) Delisted | Mixed | −75,310 | $0 | EDGAR |
| 2025-08-05 | 89bio, Inc. (ETNB) Delisted | Tax (F) | −6,185 | -$58.2K | EDGAR |
| 2025-02-04 | 89bio, Inc. (ETNB) Delisted | Grant (A) | +53,750 | $0 | EDGAR |
| 2024-08-07 | 89bio, Inc. (ETNB) Delisted | Grant (A) | +25,000 | $0 | EDGAR |
| 2023-08-25 | — | Mixed | −155,419 | -$12.0K | |
| 2023-06-23 | Apexigen, Inc. (APGNW) Delisted | Tax (F) | −6,917 | -$3.4K | EDGAR |
| 2023-05-25 | Apexigen, Inc. (APGNW) Delisted | Mixed | +129,252 | -$8.3K | EDGAR |
| 2022-12-19 | Apexigen, Inc. (APGNW) Delisted | Tax (F) | −6,916 | -$7.3K | EDGAR |
| 2022-10-11 | Apexigen, Inc. (APGNW) Delisted | Grant (A) | +40,000 | $0 | EDGAR |
| 2021-04-19 | FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | Mixed | −123,927 | -$6.50M | EDGAR |